Abstract 12142: Cardiovascular Associations of Chimeric Antigen Receptor T-cell Therapy: A Retrospective Cohort Study From National Inpatient Sample 2016-2019

Abstract

Introduction: After FDA approval in 2017, chimeric antigen receptor (CAR) T-cell therapy gained high popularity in various hematological malignancies. Hypothesis: There are no sex-based differences in in-hospital mortality and length of stay after CAR T-cell therapy. Methods and Results: From 2018 to 2019, using national inpatient sample, among a total of 14,189,303 hospitalizations (unweighted sample) 704 (0.01%) CAR T-cell therapy were performed, 306 in 2018 and 408 in 2019. Among the CAR T-cell therapy performed, 58.4% (n = 417) were males, 2.9% (n=21) had pulmonary edema, 0.6% (n=6) had acute decompensated heart failure, 3.08% (n=22) had supraventricular tachycardia, 3.36% (n=24) had ventricular tachycardia, 1.94% (n=14) had pericardial effusion (including chronic pericarditis or tamponade), 0.14% (n=1) had acute pericarditis, 0.14% (n=1) had non ST-segment elevation myocardial infarction, 3.64% (n=26) required pressors, 8.68% (n=64) had atrial fibrillation, 3.64% (n=26) had disseminated intravascular coagulation, 4.76% (n=34) required mechanical ventilation. 3.92% (n=28) died in the hospital and mean length of stay (LOS) was 20.5 days. The mean age for CAR T-cell therapy was 54 ± 18 years. Among CAR T cell therapy population, compared to males, females were similar in age (mean age: 54.6 vs. 54 years; p=0.606), had lower incidence of atrial fibrillation (4.38% vs 11.75%, p<0.001) but similar in-hospital mortality (3% vs 4.6%, p=0.334) and similar LOS (21 days vs 20 days, p=0.740). Conclusions: CAR T cell therapy is associated with few cardiovascular conditions. We did not find sex-based differences in in-hospital mortality or LOS in CAR T cell therapy.